Nimodipine
FDA Approved, EMA Approved
Contents
Description
Nimodipine is a dihydropyridine calcium channel blocker with preferential cerebrovascular effects. It is specifically indicated for improving neurological outcomes following aneurysmal subarachnoid hemorrhage by reducing cerebral vasospasm. The drug crosses the blood-brain barrier and has neuroprotective properties.
Indications & Therapeutic Use
aneurysmal subarachnoid hemorrhage, cerebral vasospasm prevention
Linked Diseases:
Global Availability (8 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Nimodipine — GNH India
94 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Befimat
EU
Brainal
EU
Brainox
EU
Curban
EU
Dilceren
EU
Dilceren Pro Infusione
EU
Iskidrop
EU
Modina
EU
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Nimodipine
| Generic Name | nimodipine |
| Brands | 1 brand available |
| Active Ingredient | nimodipine |
| Drug Class | aneurysmal subarachnoid hemorrhage |
| Manufacturer | Bayer |
| Dosage Forms | oral capsule 30mg; oral solution 30mg/10mL |
| Medical Code | C08CA06 |
| Orphan Status | No |
| Cold Chain | Not Required |
| Lead Time | 5 days |
| Reg. Status | FDA Approved, EMA Approved |
| Clinical Trial | NCT00000544 |
| Countries | 8 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations9 Validated Nodes